A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
← catalyst calendarSponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
110estimated
Sites
1
Country
Austria
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-14 | actual | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Genital Psoriasis
Intervention
- Drug: Tildrakizumab — also filed as Ilumetri®
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of "Clear" (0) or "Almost Clear" (1)
measured Baseline up to Week 52
Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score
measured Baseline up to Week 52
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed